ORIGINAL_ARTICLE
miR-33 inhibition attenuates the effect of liver X receptor agonist T0901317 on expression of liver X receptor alpha in mice liver
BACKGROUND: microRNAs play pivotal roles in metabolism and other aspects of cell biology. microRNA-33 and liver X receptor (LXR) affect lipid metabolism and cholesterol trafficking. In this study, we evaluated effects of co-administration of miR-33 inhibitor and LXR activator on LXR-α and adenosine triphosphate-binding cassette transporter A1 (ABCA1) expression in mice liver. METHODS: Twenty-four mice were randomly allocated into four groups (n = 6). Group 1 mice received standard chow diet without any treatment, group 2 received 30 mg/kg/48 hour LXR agonist (T0901317), group 3 received 1 mg/kg/48 hour in vivo locked nucleic acids (LNA) anti-miR-33 and group 4 received both T0901317 and in vivo LNA anti-miR-33. All treatments were administrated through intraperitoneal injection (IP). After 7 days and at the end of the study, mice were sacrificed, liver tissues were excised and blood samples were collected. LXR-α and ABCA1 genes and protein expression were quantified by real-time polymerase chain reaction (PCR) and western blotting, respectively. RESULTS: LXR activation caused LXR-α and ABCA1 mRNA (P < 0.050) and protein elevation as compared to control (P < 0.001). miR-33 inhibition attenuates T0901317 effect on LXR-α expression in group IV. Co-administration of T0901317 and anti-miR-33 remarkably elevated high-density lipoprotein cholesterol (HDL-C) levels, compared to control group (P = 0.001). Separate administration of T0901317 and anti-miR-33 also elevated HDL-C levels (P < 0.010). CONCLUSION: Co-administration of T0901317 and anti-miR-33 can be considered as a good therapeutic alternative for atherosclerosis because miR-33 inhibition reduced lipogenic effects of LXR-α activator and also helps LXR-α agonist to increase reverse cholesterol transport (RCT) and also HDL-C as antiatherogenic effects.
https://arya.mui.ac.ir/article_10604_0b79c55a9bbc4f9a78787efce7340cba.pdf
2017-11-19
257
263
Atherosclerosis
mir-33 Human
T0901317
Liver X Receptor-Alpha
ABCA1 Protein
Abbas
Mohammadi
edrisv71@yahoo.com
1
Professor, Physiology Research Center AND Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman AND Sirjan School of Medical Sciences, Sirjan, Iran
AUTHOR
Hossein
Fallah
2
Assistant Professor, Physiology Research Center AND Department of Clinical Biochemistry, Afzalipour School of Medicine,, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Beydolah
Shahouzehi
bshahouzehi@gmail.com
3
Physiology Research Center AND Department of Clinical Biochemistry, Afzalipour School of Medicine Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Hamid
Najafipour
4
Professor, Physiology Research Center AND Department of Physiology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Najafi-Shoushtari SH. MicroRNAs in cardiometabolic disease. Curr Atheroscler Rep 2011; 13(3): 202-7.
1
Ramirez CM, Rotllan N, Vlassov AV, Davalos A, Li M, Goedeke L, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res 2013; 112(12): 1592-601.
2
Soumian S, Albrecht C, Davies AH, Gibbs RG. ABCA1 and atherosclerosis. Vasc Med 2005; 10(2): 109-19.
3
Annema W, Dikkers A, de Boer JF, Gautier T, Rensen PC, Rader DJ, et al. ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. J Lipid Res 2012; 53(5): 929-40.
4
Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc 2012; 1(6): e003376.
5
Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13(4): 239-50.
6
Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, Rader DJ. Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Circulation 2011; 124(12): 1382-90.
7
Basso F, Freeman L, Knapper CL, Remaley A, Stonik J, Neufeld EB, et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res 2003; 44(2): 296-302.
8
Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30(8): 1513-8.
9
Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J Endocrinol 2010; 204(3): 233-40.
10
Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, et al. Activation of liver X receptor decreases atherosclerosis in Ldlr(-)/(-) mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler Thromb Vasc Biol 2014; 34(2): 279-84.
11
Chisholm JW, Hong J, Mills SA, Lawn RM. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 2003; 44(11): 2039-48.
12
Baranowski M. Biological role of liver X receptors. J Physiol Pharmacol 2008; 59(Suppl 7): 31-55.
13
Ma Z, Deng C, Hu W, Zhou J, Fan C, Di S, et al. Liver X Receptors and their Agonists: Targeting for Cholesterol Homeostasis and Cardiovascular Diseases. Curr Issues Mol Biol 2017; 22: 41-64.
14
Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 2003; 536(1-3): 6-11.
15
Li M, Meng X, Xu J, Huang X, Li H, Li G, et al. GPR40 agonist ameliorates liver X receptor-induced lipid accumulation in liver by activating AMPK pathway. Sci Rep 2016; 6: 25237.
16
Yap F, Craddock L, Yang J. Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int J Biol Sci 2011; 7(5): 645-50.
17
Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW, et al. AMP-activated protein kinase suppresses the expression of LXR/SREBP-1 signaling-induced ANGPTL8 in HepG2 cells. Mol Cell Endocrinol 2015; 414: 148-55.
18
He F, Han C, Liu D, Wan H, Wang J, Liu H, et al. Effect of a synthetic liver X receptor agonist TO901317 on cholesterol concentration in goose primary hepatocytes. Ital J Anim Sci 2014; 13(1): 2979.
19
Kostopoulou F, Malizos KN, Papathanasiou I, Tsezou A. MicroRNA-33a regulates cholesterol synthesis and cholesterol efflux-related genes in osteoarthritic chondrocytes. Arthritis Res Ther 2015; 17: 42.
20
Najafipour H, Vakili A, Shahouzehi B, Soltani HA, Masoomi Y, Yeganeh Hajahmadi M, et al. Investigation of changes in apelin receptor mRNA and protein expression in the myocardium and aorta of rats with two-kidney, one-clip (2K1C) Goldblatt hypertension. J Physiol Biochem 2015; 71(2): 165-75.
21
Zheng F, Zhang S, Lu W, Wu F, Yin X, Yu D, et al. Regulation of insulin resistance and adiponectin signaling in adipose tissue by liver X receptor activation highlights a cross-talk with PPARgamma. PLoS One 2014; 9(6): e101269.
22
Fulco M, Sartorelli V. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle 2008; 7(23): 3669-79.
23
Rohrl C, Eigner K, Winter K, Korbelius M, Obrowsky S, Kratky D, et al. Endoplasmic reticulum stress impairs cholesterol efflux and synthesis in hepatic cells. J Lipid Res 2014; 55(1): 94-103.
24
Bommer GT, MacDougald OA. Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus. Cell Metab 2011; 13(3): 241-7.
25
Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010; 285(44): 33652-61.
26
Gharipour M, Sadeghi M. Pivotal role of microRNA-33 in metabolic syndrome: A systematic review. ARYA Atheroscler 2013; 9(6): 372-6.
27
Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328(5985): 1570-3.
28
Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13(4): 376-88.
29
ORIGINAL_ARTICLE
Air pollution and cardiovascular and respiratory disease: Rationale and methodology of CAPACITY study
BACKGROUND: Considering the high level of air pollution and its impact on health, we aimed to study the correlation of air pollution with hospitalization and mortality of cardiovascular (CVD) and respiratory diseases (ResD) (CAPACITY) to determine the effects of air pollutants on CVD and ResD hospitalizations and deaths in Isfahan, Iran.METHODS: Hourly levels of air pollutants including particulate matter (PM), carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), and ozone (O3), information of CVD and ResD admissions and death certificate were obtained respectively from Department of Environment (DOE), Iran, hospitals and cemetery. Time series and case-crossover model were used to find the impact of air pollutants. This paper only summarizes the descriptive findings of the CAPACITY study.RESULTS: The total number of hospitalized patients were 23781 in 2010 and 22485 in 2011. The most frequent cause of hospitalization and death was ischemic heart diseases in both years. While the mean annual levels of O3, CO, and PM10 were lower in 2011 than in 2010, NO2 and SO2 levels higher in 2011. In both years, PM10 was similarly increased during last month of fall, late spring and early summer. In 2011, the PM2.5 and PM10 monthly trend of change were similar.CONCLUSION: The CAPACITY study is one of the few large-scale studies that evaluated the effects of air pollutants on a variety of CVD and ResD in a large city of Iran. This study can provide many findings that could clarify the effects of these pollutants on the incidence and burden of both disease groups.
https://arya.mui.ac.ir/article_10605_6e5c617adab19ee772f3b7a8376a3229.pdf
2017-11-19
264
273
Air Pollution
Cardiovascular Diseases
Respiratory Tract Diseases
Katayoun
Rabiei
1
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Sayed Mohsen
Hosseini
hosseini@hlth.mui.ac.ir
2
Department of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Erfan
Sadeghi
3
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
AUTHOR
Tohid
Jafari-Koshki
4
Road Traffic Injury Research Center AND Department of Statistics and Epidemiology, School of Health, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Mojtaba
Rahimi
5
Department of Anesthesiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mansour
Shishehforoush
shishe@fsaco.ir
6
Isfahan Disaster Management Office, Isfahan Governer’s Office, Isfahan, Iran
AUTHOR
Ahmadreza
Lahijanzadeh
7
Khouzestan Department of Environment, Ahvaz, Iran
AUTHOR
Babak
Sadeghian
8
Central Laboratory and Air Pollution Monitoring, Isfahan Province Environmental Monitoring Center, Isfahan Department of Environment, Isfahan, Iran
AUTHOR
Elham
Moazam
9
Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mohammad Bagher
Mohebi
10
Information Technology Offices, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Victoria
Ezatian
11
Isfahan Meteorological Offices, Isfahan, Iran
AUTHOR
Nizal
Sarrafzadegan
nsarrafzadegan@gmail.com
12
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Cesaroni G, Badaloni C, Gariazzo C, Stafoggia M, Sozzi R, Davoli M, et al. Long-term exposure to urban air pollution and mortality in a cohort of more than a million adults in Rome. Environ Health Perspect 2013; 121(3): 324-31.
1
Fischer PH, Marra M, Ameling CB, Hoek G, Beelen R, de Hoek K, et al. Air pollution and mortality in seven million adults: The Dutch environmental longitudinal study (DUELS). Environ Health Perspect 2015; 123(7): 697-704.
2
World Health Organization. Burden of disease from Ambient Air Pollution for 2012. Geneva, Switzerland: WHO; 2012.
3
Anderson JO, Thundiyil JG, Stolbach A. Clearing the air: A review of the effects of particulate matter air pollution on human health. J Med Toxicol 2012; 8(2): 166-75.
4
Ji M, Cohan DS, Bell ML. Meta-analysis of the Association between Short-Term Exposure to Ambient Ozone and Respiratory Hospital Admissions. Environ Res Lett 2011; 6(2).
5
Perez L, Grize L, Infanger D, Kunzli N, Sommer H, Alt GM, et al. Associations of daily levels of PM10 and NO(2) with emergency hospital admissions and mortality in Switzerland: Trends and missed prevention potential over the last decade. Environ Res 2015; 140: 554-61.
6
Pope CA 3rd, Turner MC, Burnett RT, Jerrett M, Gapstur SM, Diver WR, et al. Relationships between fine particulate air pollution, cardiometabolic disorders, and cardiovascular mortality. Circ Res 2015; 116(1): 108-15.
7
Roberts S. Interactions between particulate air pollution and temperature in air pollution mortality time series studies. Environ Res 2004; 96(3): 328-37.
8
McGranahan G, Murray F. Air pollution and health in rapidly developing countries. London, UK: Routledge; 2012.
9
World Health Organization. Database: Outdoor air pollution in cities: Public health, environmental and social determinants of health (PHE) [Online]. [cited 2011]; Available from: URL:
10
http://www.who.int/phe/health_topics/outdoorair/databases/cities-2011/en
11
Hosseinpoor AR, Forouzanfar MH, Yunesian M, Asghari F, Naieni KH, Farhood D. Air pollution and hospitalization due to angina pectoris in Tehran, Iran: A time-series study. Environ Res 2005; 99(1): 126-31.
12
Qorbani M, Yunesian M, Fotouhi A, Zeraati H, Sadeghian S. Effect of air pollution on onset of acute coronary syndrome in susceptible subgroups. East Mediterr Health J 2012; 18(6): 550-5.
13
Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: The Isfahan Cohort Study. Arch Iran Med 2013; 16(3): 138-44.
14
Shirani S, Kelishadi R, Sarrafzadegan N, Khosravi A, Sadri G, Amani A, et al. Awareness, treatment and control of hypertension, dyslipidaemia and diabetes mellitus in an Iranian population: The IHHP study. East Mediterr Health J 2009; 15(6): 1455-63.
15
Sarrafzadegan N, Baghaei A, Sadri G, Kelishadi R, Malekafzali H, Boshtam M, et al. Isfahan healthy heart program: Evaluation of comprehensive, community-based interventions for non-communicable disease prevention. Prevention and Control 2006; 2(2): 73-84.
16
Mohammadifard N, Khaledifar A, Khosravi A, Nouri F, Pourmoghadas A, Feizi A, et al. Dietary sodium and potassium intake and their association with blood pressure in a non-hypertensive Iranian adult population: Isfahan salt study. Nutr Diet 2017; 74(3): 275-82.
17
Rabiei K, Kelishadi R, Sarrafzadegan N, Sadri G, Amani A. Short-term results of community-based interventions for improving physical activity: Isfahan Healthy Heart Programme. Arch Med Sci 2010; 6(1): 32-9.
18
Sarrafzadegan N, Kelishadi R, Esmaillzadeh A, Mohammadifard N, Rabiei K, Roohafza H, et al. Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in the Islamic Republic of Iran. Bull World Health Organ 2009; 87(1): 39-50.
19
Gandomkar A. A Statistical Study of Isfahan Air Polluted Days. Proceedings of the 4th International Conference on Chemical, Ecology and Environmental Sciences (ICEES'2015); 2015 Dec. 15-16; Pattaya, Thailand.
20
Islamic Republic of Iran Vice Presidency for Strategic Planning and Supervision Statistical Centre of Iran. Selected findings of national population and housing census, 2011 [Online]. [cited 2011]; Available from: URL:
21
https://www.amar.org.ir/Portals/1/Iran/90.pdf
22
Uganda Bureau of Statistics. National Population
23
and Housing Census 2014; Main Report [Online]. [cited 2016]; Available from: URL:
24
https://unstats.un.org/unsd/demographic/sources/census/wphc/Uganda/UGA-2016-05-23.pdf
25
Peel MC, Finlayson BL, McMahon TA. Updated world map of the Koppen-Geiger climate classification. Hydrol Earth Syst Sci 2007; 11: 1633-44.
26
Abbasnia M, Tavousi T, Khosravi M, Toros H. Interactive effects of urbanization and climate change during the last decades (A case study: Isfahan city). Eur J Sci Technol 2016; 4(7).
27
Khosravi A, Aghamohamadi S, Kazemi E, Pour Malek F, Shariati M. Mortality profile in Iran (29 provinces) over the years 2006 to 2010. Tehran, Iran: Ministry of Health and Medical Education; 2013. p. 413-4.
28
Encyclopędia Iranica. Isfahan xiv. modern economy and industries (2) Isfahan City: xiv. Modern Economy and Industries [Online]. [cited 2016]; Available from: URL:
29
http://www.iranicaonline.org/articles/isfahan-xiv2-industries-of-isfahan-city
30
World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland: WHO; 2010.
31
Abedian S, Bitaraf E. The Framework for Evaluation of Hospital Information System in Iran. Tehran, Iran: The office of statistics and Technology-Ministry of Health; 2010.
32
Sepehrnia S. Instructions for air pollution monitoring stations: Iran Department of Environment [Online]. [cited 2015]; Available from: URL: https://www.doe.ir/Portal/file/?681739
33
Gordon EL. History of the Modern Environmental Movement in America [Online]. [cited 2012]; Available from: URL:
34
https://photos.state.gov/libraries/mumbai/498320/fernandesma/June_2012_001.pdf
35
Schrenk HH. Air pollution in Donora, PA: Epidemiology of the unusual smog episode of October 1948. Washington, DC: Federal Security Agency, Public Health Service, Bureau of State Services, Division of Industrial Hygiene; 1949.
36
Wilkins ET. Air pollution and the London fog of December, 1952. J R Sanit Inst 1954; 74(1): 1-15.
37
Brimblecombe P. The Clean Air Act after 50 years. Weather 2006; 61(11): 311-4.
38
Stern AC. History of air pollution legislation in the United States. J Air Pollut Control Assoc 1982; 32(1): 44-61.
39
World Health Organization. Air quality guidelines. Global update 2005. Particulate matter, ozone, nitrogen dioxide and sulfur dioxide [Online]. [cited 2006]; Available from: URL:
40
http://www.euro.who.int/en/health-topics/environment-and-health/air-quality/publications/pre2009/air-quality-guidelines.-global-update-2005.-particulate-matter,-
41
ozone,-nitrogen-dioxide-and-sulfur-dioxide
42
Chiu HF, Peng CY, Wu TN, Yang CY. Short-term effects of fine particulate air pollution on ischemic heart disease hospitalizations in Taipei: A case-crossover study. Aerosol Air Qual Res 2013; 13(5): 1563-9.
43
Wichmann J, Voyi K. Ambient air pollution exposure and respiratory, cardiovascular and cerebrovascular mortality in Cape Town, South Africa: 2001-2006. Int J Environ Res Public Health 2012; 9(11): 3978-4016.
44
Naddafi K, Hassanvand MS, Yunesian M, Momeniha F, Nabizadeh R, Faridi S, et al. Health impact assessment of air pollution in megacity of Tehran, Iran. Iranian J Environ Health Sci Eng 2012; 9(1): 28.
45
Geravandi S, Goudarzi G, Salmanzadeh S, Beyt Mashal S, Mohammadi M, Naiemabadi A. Determination of cardiovascular deaths and hospital admissions due to respiratory disease for particulate matter less than 10 microns exposure in Ahvaz city during 2010-2012. J Rafsanjan Univ Med Sci 2016; 14 (10): 853-64. [In Persian].
46
Goudarzi G, Geravandi S. Saeidimehr M.J, Mohammadi M, Vosoughi Niri S, Salmanzadeh 5, et al. Estimation of health effects for PM10 exposure using of Air Q model in Ahvaz City during 2009. Iran J Health Environ 2015; 8(1): 117-26. [In Persian].
47
Hosseini G, Maleki A, Amini H, Mohammadi S, Hassanvand MS, Giahi O, et al. Health impact assessment of particulate matter in Sanandaj, Kurdistan, Iran. J Adv Environ Health Res 2014; 2(1): 54-62.
48
Ebrahimi SJ, Ebrahimzadeh L, Eslami A, Bidarpoor F. Effects of dust storm events on emergency admissions for cardiovascular and respiratory diseases in Sanandaj, Iran. J Environ Health Sci Eng 2014; 12: 110.
49
Khamutian R, Najafi F, Soltanian M, Shokoohizadeh MJ, Poorhaghighat S, Dargahi A, et al. The association between air pollution and weather conditions with increase in the number of admissions of asthmatic patients in emergency wards: A case study in Kermanshah. Med J Islam Repub Iran 2015; 29: 229.
50
Mansourian M, Javanmard SH, Poursafa P, Kelishadi R. Air pollution and hospitalization for respiratory diseases among children in Isfahan, Iran. Ghana Med J 2010; 44(4): 138-43.
51
Rashidi M, Ghias M, Ramesht MH. Geographical epidemiology of death due to cardiovascular diseases in Isfahan Province, Iran. J Isfahan Med Sch 2011; 29(125): 13-9. [In Persian].
52
ORIGINAL_ARTICLE
An investigation of the psychological experiences of patients under mechanical ventilation following open heart surgery
BACKGROUND: Breathing and living on mechanical ventilation develops a different feeling in patients. Most of such feelings and experiences are not pleasant and can lead to psychiatric disorders in the patients after they are detached from the ventilator. The aim of this study is to explore the psychological experiences of patients under mechanical ventilation. METHODS: This qualitative study was conducted according to an interpretive epistemological approach in 2016. Fifteen participants were selected according to purposive sampling. Data were drawn from the transcripts of in-depth, semi-structured interview that were not discontinued until data saturation was ensured. The participants were asked to share what they experienced when they were under mechanical ventilation and intubation. Data analysis was conducted according to Diekelmann method. RESULTS: Altogether, 2 themes, 7 subthemes, and 27 sub-subthemes were drawn from the data. Two themes were dread (a horrible experience) and hope (an inspiring experience). Dread consisted of anxiety, hopelessness, and dependency. Hope consisted of spiritual connection as the only possible effort, the presence of health team the source of comfort, the family looking forward, and overcoming the illness (a step to life). CONCLUSION: The psychological experiences of patients under mechanical ventilation are specific, and nurses can play an important role in decreasing tension and increasing hope among them through gaining knowledge about their experiences.
https://arya.mui.ac.ir/article_10606_cc7174e2c9f1053e7853a10e219a5660.pdf
2017-11-19
274
281
Mechanical Ventilation
Psychology
Patients
Heart Surgery
Yousef
Aslani
1
Department of Medical Surgery Nursing, School of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, Iran
AUTHOR
Reyhaneh
Niknezhad
2
MSc Student, Nursing and Midwifery Student Research Committee AND Department of Operative Room, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Maryam
Moghimian
3
PhD Candidate, Nursing and Midwifery Sciences Development Research Center AND Department of Nursing, School of Nursing and Midwifery, Najafabad Branch, Islamic Azad University, Najafabad, Iran
AUTHOR
Jaefar
Maghaddasi
4
PhD Candidate, Department of Medical Surgery Nursing, School of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, Iran
AUTHOR
Mohammad
Akbari
mohammadakbari@nm.mui.ac.ir
5
PhD Candidate, Nursing and Midwifery Student Research Committee AND Department of Mental Health Nursing, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Engstrom A, Nystrom N, Sundelin G, Rattray J. People’s experiences of being mechanically ventilated in an ICU: A qualitative study. Intensive Crit Care Nurs 2013; 29(2): 88-95.
1
Rose L, Nonoyama M, Rezaie S, Fraser I. Psychological wellbeing, health related quality of life and memories of intensive care and a specialised weaning centre reported by survivors of prolonged mechanical ventilation. Intensive Crit Care Nurs 2014; 30(3): 145-51.
2
Tsay SF, Mu PF, Lin S, Wang KW, Chen YC. The experiences of adult ventilator-dependent patients: A meta-synthesis review. Nurs Health Sci 2013; 15(4): 525-33.
3
Akhtar MI, Hamid M, Minai F, Wali AR, Anwar UH, Aman-Ullah M, et al. Safety profile of fast-track extubation in pediatric congenital heart disease surgery patients in a tertiary care hospital of a developing country: An observational prospective study. J Anaesthesiol Clin Pharmacol 2014; 30(3): 355-9.
4
Breckenridge SJ, Chlan L, Savik K. Impact of tracheostomy placement on anxiety in mechanically ventilated adult ICU patients. Heart Lung 2014; 43(5): 392-8.
5
Nguyen YL, Perrodeau E, Guidet B, Trinquart L, Richard JC, Mercat A, et al. Mechanical ventilation and clinical practice heterogeneity in intensive care units: A multicenter case-vignette study. Ann Intensive Care 2014; 4(1): 2.
6
Hardin SR, Kaplow R. Cardiac surgery essentials for critical care nursing. Burlington, MA: Jones & Bartlett Learning; 2010.
7
Crocker C, Kinnear W. Weaning from ventilation: Does a care bundle approach work? Intensive Crit Care Nurs 2008; 24(3): 180-6.
8
Egbers PH, Bultsma R, Middelkamp H, Boerma EC. Enabling speech in ICU patients during mechanical ventilation. Intensive Care Med 2014; 40(7): 1057-8.
9
Coyer FM, Wheeler MK, Wetzig SM, Couchman BA. Nursing care of the mechanically ventilated patient: What does the evidence say? Part two. Intensive Crit Care Nurs 2007; 23(2): 71-80.
10
Elder NC, Brungs SM, Nagy M, Kudel I, Render ML. Nurses’ perceptions of error communication and reporting in the intensive care unit. J Patient Saf 2008; 4(3): 162-8.
11
Eckerblad J, Eriksson H, Karner A, Edell-Gustafsson U. Nurses’ conceptions of facilitative strategies of weaning patients from mechanical ventilation-a phenomenographic study. Intensive Crit Care Nurs 2009; 25(5): 225-32.
12
MacIntyre N. Discontinuing mechanical ventilatory support. Chest 2007; 132(3): 1049-56.
13
Schou L, Egerod I. A qualitative study into the lived experience of post-CABG patients during mechanical ventilator weaning. Intensive Crit Care Nurs 2008; 24(3): 171-9.
14
Schandl AR. Physical and psychological problems after critical illness prediction, detection and treatment. Stockholm, Sweden: Karolinska Institutet; 2013.
15
Jubran A, Lawm G, Duffner LA, Collins EG, Lanuza DM, Hoffman LA, et al. Post-traumatic stress disorder after weaning from prolonged mechanical ventilation. Intensive Care Med 2010; 36(12): 2030-7.
16
Karlsson V, Bergbom I, Forsberg A. The lived experiences of adult intensive care patients who were conscious during mechanical ventilation: A
17
phenomenological-hermeneutic study. Intensive Crit Care Nurs 2012; 28(1): 6-15.
18
Speziale HS, Streubert HJ, Carpenter DR. Qualitative research in nursing: Advancing the humanistic imperative. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.
19
Diekelmann N, Allen D, Tanner CA. The NLN criteria for appraisal of baccalaureate programs: A critical hermeneutic analysis. Washington, DC: National League for Nursing; 1989.
20
Loghmani L, Borhani F, Abbaszadeh A. Determination of the content of communication between the care team and family members of patients in the intensive care unit: The experience of nurses and patients’ families. J Qual Res Health Sci 2014; 3(3): 257-68. [In Persian].
21
Rezaee N, Rafii F, Mardani M, Ranjbar H. A concept analysis of hope of patient recovery among nurses in intensive care: A hybrid model. J Qual Res Health Sci 2013; 2(2): 101-10. [In Persian].
22
Abedi HA, Monemiyan S, Naji SA. Spiritual-psychological experiences of heart transplant recipientS. J Qual Res Health Sci 2012; 1(1): 52-8. [In Persian].
23
Foster A. More than nothing: The lived experience of tracheostomy while acutely ill. Intensive Crit Care Nurs 2010; 26(1): 33-43.
24
Arslanian-Engoren C, Scott LD. The lived experience of survivors of prolonged mechanical ventilation: A phenomenological study. Heart Lung 2003; 32(5): 328-34.
25
Wang K, Zhang B, Li C, Wang C. Qualitative analysis of patients’ intensive care experience during mechanical ventilation. J Clin Nurs 2009; 18(2): 183-90.
26
Khayyam-Nekouei Z, Neshatdoost H, Yousefy A, Sadeghi M, Manshaee G. Psychological factors and coronary heart disease. ARYA Atheroscle 2013; 9(1): 102-11.
27
ORIGINAL_ARTICLE
The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study
BACKGROUND: The major aim of this study was evaluating the effect of atorvastatin treatment on thiobarbituric acid reactive substances (TBARS), ferric reducing the ability of plasma (FRAP), small dense low-density lipoprotein cholesterol (sdLDL) and lipid profile in coronary artery disease (CAD) patients.METHODS: This study was carried out on 83 patients with angiographically proven coronary artery stenosis (52 men and 31 women) at Shahid Madani Hospital, Khorramabad, Iran, in 2015. The patients were divided into the 3 groups. 27 patients were classified statins consumption less than 6 days, 28 patients for 6 to 90 days, and 28 patients for more than 90 days. The level of sdLDL, lipid profile, TBARS and FRAP were assayed.RESULTS: FRAP levels of patients that received atorvastatin for more than 90 days (832 ± 101) were significantly elevated (P = 0.01) compared to the patients received atorvastatin less than 6 days (688 ± 75), whereas the levels of TBARS diminished significantly (P = 0.04). Also, the levels of total cholesterol (TC) and LDL-C were significantly decreased after 3 months of atorvastatin receiving (158 as compared to patients that consumed atorvastatin less than 6 days), (P = 0.02 and 0.03, respectively). The level of sdLDL was slightly increased with long-time consumption of atorvastatin (37 ± 14) in patients in comparison with patients that received atorvastatin less than 6 days (32 ± 15) (P = 0.06), but was not significant.CONCLUSION: The serum level of TBARS decreased and the serum level of FRAP increased in patients with long-time receiving atorvastatin. Therefore, atorvastatin contributes to the lowering oxidative stress in these patients.
https://arya.mui.ac.ir/article_10607_160f5792b09ad778e8d6913aa550e347.pdf
2017-11-19
282
287
Atorvastatin
Coronary Artery Disease
Oxidative Stress
Gholamreza
Shahsavari
1
Assistant Professor, Department of Clinical Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Amir
Raoufi
dr.raoufi@gmail.com
2
Assistant Professor, Department of Cardiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Aram
Toolabi
toolabi_a@yahoo.com
3
Assistant Professor, Department of Cardiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Nahid
Hosseninejadmir
4
Assistant Professor, Department of Cardiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Hassan
Ahmadvand
hassan_a46@yahoo.com
5
Professor, Herbal Medicine Research Center AND Department of Clinical Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
LEAD_AUTHOR
Mehdi
Safariebrahimsarabie
6
Young Researchers, Elite Club Yadegar-e-Imam Khomeini (RAH), Shahr-e-Rey Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Favero G, Paganelli C, Buffoli B, Rodella LF, Rezzani R. Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int 2014; 2014: 801896.
1
Liu Q, Wang S, Cai L. Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage. J Diabetes Investig 2014; 5(6): 623-34.
2
Ahmadvand H, Mabuchi H, Nohara A, Kobayahi J, Kawashiri MA. Effects of coenzyme Q(10) on LDL oxidation in vitro. Acta Med Iran 2013; 51(1): 12-8.
3
Ahmadvand H, Noori A, Dehnoo MG, Bagheri S, Cheraghi RA. Hypoglycemic, hypolipidemic and antiatherogenic effects of oleuropein in alloxan-induced Type 1 diabetic rats. Asian Pac J Trop Dis 2014; 4(Supplement 1): S421-S425.
4
Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43(9): 1363-79.
5
Kwon SW, Yoon SJ, Kang TS, Kwon HM, Kim JH, Rhee J, et al. Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med J 2006; 47(3): 405-14.
6
Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 2004; 24(3): 558-63.
7
Singh N, Singh N, Kumar SS, Kumar SA, Kafle D, Agrawal N. Reduced antioxidant potential of LDL is associated with increased susceptibility to LDL peroxidation in type II diabetic patients. Int J Endocrinol Metab 2012; 10(4): 582-6.
8
Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31(Pt 5): 1066-9.
9
Tian L, Li C, Liu Y, Chen Y, Fu M. The value and distribution of high-density lipoprotein subclass in patients with acute coronary syndrome. PLoS One 2014; 9(1): e85114.
10
Domingos H, Cunha RV, Paniago AM, Souza AS, Rodrigues RL, Domingos JA. Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV. Arq Bras Cardiol 2012; 99(5): 997-1007.
11
Huang YC, Chang PY, Hwang JS, Ning HC. Association of small dense lowdensity lipoprotein cholesterol in type 2 diabetics with coronary artery disease. Biomed J 2014; 37(6): 375-9.
12
Llurba E, Casals E, Dominguez C, Delgado J, Mercade I, Crispi F, et al. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. Metabolism 2005; 54(11): 1504-9.
13
Gentile M, Panico S, Mattiello A, Ubaldi S, Iannuzzo G, De Michele M, et al. Association between small dense LDL and early atherosclerosis in a sample of menopausal women. Clin Chim Acta 2013; 426: 1-5.
14
Nozue T, Michishita I, Ishibashi Y, Ito S, Iwaki T, Mizuguchi I, et al. Small dense low-density lipoprotein cholesterol is a useful marker of metabolic syndrome in patients with coronary artery disease. J Atheroscler Thromb 2007; 14(4): 202-7.
15
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
16
Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis 2013; 231(1): 8-14.
17
Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004; 15(5): 251-8.
18
Ahmadvand H, Tavafi M, Khosrowbeygi A, Shahsavari G, Hormozi M, Beyranvand K, et al. Amelioration of lipid peroxidation in vivo and in vitro by Satureja khozestanica essential oil in alloxan-induced diabetic rats. J Diabetes Metab Disord 2014; 13(1): 119.
19
Bolanos de la Torre AA, Henderson T, Nigam PS, Owusu-Apenten RK. A universally calibrated microplate ferric reducing antioxidant power (FRAP) assay for foods and applications to Manuka honey. Food Chem 2015; 174: 119-23.
20
Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small, dense LDL. J Lipid Res 2003; 44(11): 2193-201.
21
Ahmadvand H, Ghasemi-Dehnoo M. Antiatherogenic, hepatoprotective, and hypolipidemic effects of coenzyme Q10 in alloxan-induced type 1 diabetic rats. ARYA Atheroscler 2014; 10(4): 192-8.
22
Pandey KB, Rizvi SI. Biomarkers of oxidative stress in red blood cells. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155(2): 131-6.
23
Ahmadvand H, Tavafi M, Khosrowbeygi A. Amelioration of altered antioxidant enzymes activity and glomerulosclerosis by coenzyme Q10 in alloxan-induced diabetic rats. J Diabetes Complications 2012; 26(6): 476-82.
24
Majsterek I, Malinowska K, Stanczyk M, Kowalski M, Blaszczyk J, Kurowska AK, et al. Evaluation of oxidative stress markers in pathogenesis of primary open-angle glaucoma. Exp Mol Pathol 2011; 90(2): 231-7.
25
Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008; 102(3): 321-5.
26
Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008; 51(17): 1653-62.
27
Tavridou A, Efthimiadis A, Efthimiadis I, Paschalidou H. Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease. Eur J Clin Pharmacol 2006; 62(6): 485-9.
28
Hsue PY, Bittner VA, Betteridge J, Fayyad R, Laskey R, Wenger NK, et al. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. Am J Cardiol 2015; 115(4): 447-53.
29
Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, et al. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. Transplantation 2014; 97(12): 1266-71.
30
Yoshino G, Nakano S, Matsumoto T, Murakami E, Morita T, Kuboki K. Rosuvastatin Reduces Plasma Small Dense Ldl-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients. Pharmacol Pharm 2012; 3(1): 72-8.
31
Nozue T, Michishita I, Ito Y, Hirano T. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2008; 15(3): 146-53.
32
Hosseini Gohari L, Karimzadeh Ghassab R, Firoozray M, Zavarehee A, Basiri HA. The association between small dense low density lipoprotein,apolipoprotein B, apolipoprotein B/apolipoprotein A1 ratio and coronary artery stenosis. Med J Islam Repub Iran 2009; 23(1): 8-13.
33
St-Pierre AC, Bergeron J, Pirro M, Cantin B, Dagenais GR, Despres JP, et al. Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoproteins in men (The Quebec Cardiovascular Study). Am J Cardiol 2003; 91(5): 555-8.
34
Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, Shoji M, et al. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease. J Atheroscler Thromb 2014; 21(8): 755-67.
35
Koh KK, Lim S, Choi H, Lee Y, Han SH, Lee K, et al. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. Diabetes 2013; 62(10): 3547-52.
36
Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990; 227(2): 81-94.
37
ORIGINAL_ARTICLE
The relationship between shift work and Framingham risk score: A five-year prospective cohort study
BACKGROUND: There is a small number of studies that considered the relationship between shift work (SW) and Framingham risk score (FRS). This study prospectively examined the association between SW and FRS among man workers based on the multilevel modeling approach.METHODS: This five-year prospective cohort study was done among workers (using stratified random sampling) who work in Esfahan’s Mobarakeh Steel Company (EMSC), Iran, from March 2011 to February 2015.RESULTS: The study sample included 1626 man workers (mean age = 40.0 ± 6.2). Among these subjects, 652 (40.01%), 183 (11.3%) and 791 (48.6%) were day workers, weekly rotating shift workers and routinely rotating, respectively. After controlling unbalanced variables, there was no any significant association between SW and FRS.CONCLUSION: The results of this prospective cohort study did not show a relationship between SW and FRS.
https://arya.mui.ac.ir/article_10608_07bd04e7c700cbf764ec0b39bd02aa11.pdf
2017-11-19
288
294
Framingham Risk Score
Multilevel Modeling
Prospective Cohort study
Night Shift Work
Iran
Fatemeh
Bazyar
1
MSc Student, Department of Biostatistics, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
AUTHOR
Mohammad
Gholami-Fesharaki
mohammad.gholami@modares.ac.ir
2
Assistant Professor, Department of Biostatistics, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
LEAD_AUTHOR
Mohsen
Rowzati
3
Physician of Search Disease, Worksite Follow-Up Unit, Occupational Health Center, Mobarakeh Steel Company, Isfahan, Iran
AUTHOR
Gholami Fesharaki M, Kazemnejad A, Zayeri F, Sanati J, Akbari H. Historical cohort study on the factors affecting blood pressure in workers of polyacryl iran corporation using bayesian multilevel modeling with skew T distribution. Iran Red Crescent Med J 2013; 15(5): 418-23.
1
Axelsson J, Puttonen S. Night shift work increases the risk for type 2 diabetes. Evid Based Med 2012; 17(6): 193-4.
2
McGlynn N, Kirsh VA, Cotterchio M, Harris MA, Nadalin V, Kreiger N. Shift work and obesity among Canadian women: A cross-sectional study using a novel exposure assessment tool. PLoS One 2015; 10(9): e0137561.
3
Akbari H, Mirzaei R, Nasrabadi T, Gholami-Fesharaki M. Evaluation of the effect of shift work on serum cholesterol and triglyceride levels. Iran Red Crescent Med J 2015; 17(1): e18723.
4
Suwazono Y, Uetani M, Oishi M, Tanaka K, Morimoto H, Nakada S, et al. Estimation of the benchmark duration of alternating shift work associated with increased total cholesterol levels among male Japanese workers. Scand J Work Environ Health 2010; 36(2): 142-9.
5
Lajoie P, Aronson KJ, Day A, Tranmer J. A cross-sectional study of shift work, sleep quality and cardiometabolic risk in female hospital employees. BMJ Open 2015; 5(3): e007327.
6
Eichler K, Puhan MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: A systematic review. Am Heart J 2007; 153(5): 722-31, 731.
7
Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 2002; 47(6): 408-26.
8
Bozorgmanesh M, Hadaegh F, Azizi F. Predictive accuracy of the 'Framingham's general CVD algorithm' in a Middle Eastern population: Tehran lipid and glucose study. Int J Clin Pract 2011; 65(3): 264-73.
9
Pimenta AM, Kac G, Souza RR, Ferreira LM, Silqueira SM. Night-shift work and cardiovascular risk among employees of a public university. Rev Assoc Med Bras (1992) 2012; 58(2): 168-77.
10
Kubo T, Fukuda S, Hirata K, Shimada K, Maeda K, Komukai K, et al. Comparison of coronary microcirculation in female nurses after day-time versus night-time shifts. Am J Cardiol 2011; 108(11): 1665-8.
11
Echouffo-Tcheugui JB, Batty GD, Kivimaki M, Kengne AP. Risk models to predict hypertension: A systematic review. PLoS One 2013; 8(7): e67370.
12
Murata K, Yano E, Hashimoto H, Karita K, Dakeishi M. Effects of shift work on QTc interval and blood pressure in relation to heart rate variability. Int Arch Occup Environ Health 2005; 78(4): 287-92.
13
Hublin C, Partinen M, Koskenvuo K, Silventoinen K, Koskenvuo M, Kaprio J. Shift-work and cardiovascular disease: A population-based 22-year follow-up study. Eur J Epidemiol 2010; 25(5): 315-23.
14
Yadegarfar G, McNamee R. Shift work, confounding and death from ischaemic heart disease. Occup Environ Med 2008; 65(3): 158-63.
15
Virkkunen H, Harma M, Kauppinen T, Tenkanen L. Shift work, occupational noise and physical workload with ensuing development of blood pressure and their joint effect on the risk of coronary heart disease. Scand J Work Environ Health 2007; 33(6): 425-34.
16
Sfreddo C, Fuchs SC, Merlo AR, Fuchs FD. Shift work is not associated with high blood pressure or prevalence of hypertension. PLoS One 2010; 5(12): e15250.
17
Puttonen S, Kivimaki M, Elovainio M, Pulkki-Raback L, Hintsanen M, Vahtera J, et al. Shift work in young adults and carotid artery intima-media thickness: The Cardiovascular Risk in Young Finns study. Atherosclerosis 2009; 205(2): 608-13.
18
Su TC, Lin LY, Baker D, Schnall PL, Chen MF, Hwang WC, et al. Elevated blood pressure, decreased heart rate variability and incomplete blood pressure recovery after a 12-hour night shift work. J Occup Health 2008; 50(5): 380-6.
19
Lo SH, Liau CS, Hwang JS, Wang JD. Dynamic blood pressure changes and recovery under different work shifts in young women. Am J Hypertens 2008; 21(7): 759-64.
20
Oishi M, Suwazono Y, Sakata K, Okubo Y, Harada H, Kobayashi E, et al. A longitudinal study on the relationship between shift work and the progression of hypertension in male Japanese workers. J Hypertens 2005; 23(12): 2173-8.
21
Sakata K, Suwazono Y, Harada H, Okubo Y, Kobayashi E, Nogawa K. The relationship between shift work and the onset of hypertension in male Japanese workers. J Occup Environ Med 2003; 45(9): 1002-6.
22
Ohira T, Tanigawa T, Iso H, Odagiri Y, Takamiya
23
T, Shimomitsu T, et al. Effects of shift work on 24-hour ambulatory blood pressure and its variability among Japanese workers. Scand J Work Environ Health 2000; 26(5): 421-6.
24
Knutsson A, Boggild H. Shiftwork and cardiovascular disease: Review of disease mechanisms. Rev Environ Health 2000; 15(4): 359-72.
25
Morikawa Y, Nakagawa H, Miura K, Ishizaki M, Tabata M, Nishijo M, et al. Relationship between shift work and onset of hypertension in a cohort of manual workers. Scand J Work Environ Health 1999; 25(2): 100-4.
26
Motohashi Y, Higuchi S, Maeda A, Liu Y, Yuasa T, Motohashi K, et al. Alteration of circadian time structure of blood pressure caused by night shift schedule. Occup Med (Lond) 1998; 48(8): 523-8.
27
Nazri SM, Tengku MA, Winn T. The association of shift work and hypertension among male factory workers in Kota Bharu, Kelantan, Malaysia. Southeast Asian J Trop Med Public Health 2008; 39(1): 176-83.
28
Morikawa Y, Nakagawa H, Miura K, Soyama Y, Ishizaki M, Kido T, et al. Effect of shift work on body mass index and metabolic parameters. Scand J Work Environ Health 2007; 33(1): 45-50.
29
Biggi N, Consonni D, Galluzzo V, Sogliani M, Costa G. Metabolic syndrome in permanent night workers. Chronobiol Int 2008; 25(2): 443-54.
30
Uetani M, Sakata K, Oishi M, Tanaka K, Nakada S, Nogawa K, et al. The influence of being overweight on the relationship between shift work and increased total cholesterol level. Ann Epidemiol 2011; 21(5): 327-35.
31
Gholami Fesharaki M, Kazemnejad A, Zayeri F, Rowzati M, Akbari H. Relationship between shift work and obesity a retrospective cohort study. J Mil Med 2012; 14(2): 93-7.
32
Khosravi AR, Rowzati M, Gharipour M, Fesharaki MG, Shirani S, Shahrokhi S, et al. Hypertension control in industrial employees: Findings from SHIMSCO study. ARYA Atheroscler 2012; 7(4): 191-6.
33
ORIGINAL_ARTICLE
Isolated double-orifice mitral valve in a young girl
BACKGROUND: Double-orifice mitral valve (DOMV) is an extremely rare cardiac malformation. It has been found to be accompanied by congenital anomalies (CAs), however, it can be detected as an isolated anomaly. The clinical findings of a DOMV are variable and depend predominantly on the associated cardiac abnormalities, particularly atrioventricular septal defects or mitral valve (MV) regurgitation and/or stenosis. CASE REPORT: In this regard, we describe an isolated DOMV in an 18-year-old young girl who complained of a short-term nonspecific chest pain. She underwent transthoracic and transesophageal echocardiographic examinations. The examinations revealed a DOMV without any valvular or structural malformations. Other examinations were unremarkable. The patient did need neither medical nor surgical interventions. CONCLUSION: The isolated cases of DOMV do not need therapy and might be only followed up using echocardiographic examinations. However, a careful echocardiographic examination for detection of concomitant structural malformations would be of great importance in the management of such cases.
https://arya.mui.ac.ir/article_10609_209cd3ad7103bfcd3e675c492283c56c.pdf
2017-11-19
295
298
Double Orifice Mitral Valve
Mitral Valve Disease
Congenital Heart DiseaseEchocardiography, Heart Valve Disease
Mitral Valve
Congenital Heart Defects
Niloufar
Samiei
1
Associate Professor, Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Hooman
Dehghan
2
Cardiologist, Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Maryam
Pourmojib
3
Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences,
Tehran, Iran
AUTHOR
Ahmad
Mohebbi
4
Professor, Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Saeid
Hosseini
saeid.hosseini@yahoo.com
5
Professor, Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Yousef
Rezaei
yousefrezaei1986@gmail.com
6
Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences,
Tehran, Iran
LEAD_AUTHOR
Erdemli O, Ayik I, Karadeniz U, Yamak B, Birincioglu CL, Caglar K. A double-orifice atrioventricular valve case: Intraoperative transesophageal echocardiography in diagnosis and treatment. Anesth Analg 2003; 97(3): 650-3.
1
Han J, He Y, Li Z, Zhang Y, Chen J, Wang L, et al. Isolated double-orifice mitral valve anomaly on 3-dimensional transesophageal echocardiography. J Ultrasound Med 2009; 28(11): 1589-92.
2
Khani M, Rohani A. Double-orifice mitral valve associated with bicuspid aortic valve. Asian Cardiovasc Thorac Ann 2017; 25(5): 386-7.
3
Wojcik A, Klisiewicz A, Szymanski P, Rozanski J, Hoffman P. Double-orifice mitral valve-echocardiographic findings. Kardiol Pol 2011; 69(2): 139-43.
4
Ender J, Sgouropoulou S. Value of transesophageal echocardiography (TEE) guidance in minimally invasive mitral valve surgery. Ann Cardiothorac Surg 2013; 2(6): 796-802.
5
Bano-Rodrigo A, Van PS, Trowitzsch E, Van Praagh R. Double-orifice mitral valve: A study of 27 postmortem cases with developmental, diagnostic and surgical considerations. Am J Cardiol 1988; 61(1): 152-60.
6
Zalzstein E, Hamilton R, Zucker N, Levitas A, Gross GJ. Presentation, natural history, and outcome in children and adolescents with double orifice mitral valve. Am J Cardiol 2004; 93(8): 1067-9.
7
Formigari R, Di Donato RM, Gargiulo G, Di Carlo D, Feltri C, Picchio FM, et al. Better surgical prognosis for patients with complete atrioventricular septal defect and Down's syndrome. Ann Thorac Surg 2004; 78(2): 666-72.
8
Marino B, Vairo U, Corno A, Nava S, Guccione P, Calabro R, et al. Atrioventricular canal in Down syndrome. Prevalence of associated cardiac malformations compared with patients without Down syndrome. Am J Dis Child 1990; 144(10): 1120-2.
9
Digilio MC, Marino B, Toscano A, Giannotti A, Dallapiccola B. Congenital heart defects in Kabuki syndrome. Am J Med Genet 2001; 100(4): 269-74.
10
Chatfield KC, Schrier SA, Li J, Clark D, Kaur M, Kline AD, et al. Congenital heart disease in Cornelia de Lange syndrome: Phenotype and genotype analysis. Am J Med Genet A 2012; 158A(10): 2499-505.
11
Das BB, Pauliks LB, Knudson OA, Kirby S, Chan KC, Valdes-Cruz L, et al. Double-orifice mitral valve with intact atrioventricular septum: Aan echocardiographic study with anatomic and functional considerations. J Am Soc Echocardiogr 2005; 18(3): 231-6.
12
Anwar AM, McGhie JS, Meijboom FJ, Ten Cate FJ. Double orifice mitral valve by real-time three-dimensional echocardiography. Eur J Echocardiogr 2008; 9(5): 731-2.
13
Trowitzsch E, Bano-Rodrigo A, Burger BM, Colan SD, Sanders SP. Two-dimensional echocardiographic findings in double orifice mitral valve. J Am Coll Cardiol 1985; 6(2): 383-7.
14
van Buuren F, Faber L, Bogunovic N. Double orifice mitral valve with normal function: An echocardiography and MRI study of a rare finding. Eur Heart J 2011; 32(2): 137.
15
ORIGINAL_ARTICLE
The evaluation of left ventricular diastolic dysfunction in patients with non-hemorrhagic stroke and atrial fibrillation
BACKGROUND: Atrial fibrillation (AF) is the most common tachyarrhythmia and an important risk factor for thromboembolic stroke. CHA2DS2-VASc score was introduced for assessment of embolic events and as criteria for starting anticoagulants. This study was performed to evaluate the left ventricular diastolic dysfunction (LVDD) in patients with non-hemorrhagic stroke and AF. METHODS: This cross-sectional study consisted of 76 consecutive patients with suspected non-hemorrhagic stroke referred to the Cardiology Department of Alzahra and Ayatollah Kashani hospitals in Isfahan, Iran, during 2015-2016. Demographic, anthropometric and clinical characteristics were evaluated for all patients at baseline. CHA2DS2-VASc score was calculated for all. All eligible patients underwent transthoracic echocardiogram (TTE) and LVDD was measured in the patients. RESULTS: The mean age of the patients was 64.64 ± 5.95 years and 28 subjects (36.8%) were women. The most common underlying disease in the patients was hypertension (HTN) (65.8%). Median (range) CHA2DS2-VASc score was 4 (1-7). Four patients (5.3%) had paroxysmal AF and 16 cases (21.1%) had LVDD. Analysis showed that LVDD in patients with non-hemorrhagic stroke and coexisting AF was not associated with CHA2DS2-VASc score (r = 0.151, P = 0.192). CONCLUSION: LVDD is not associated with CHA2DS2-VASc score in patients with non-hemorrhagic stroke and coexisting AF.
https://arya.mui.ac.ir/article_10610_3e7721ad9f5bf36ca9915d8c74695656.pdf
2017-11-19
299
303
Left Ventricular Dysfunction
Stroke
Atrial Fibrillation
Mahdi
Najafi-Dalui
1
Resident, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Hasan
Shemirani
shemirani@med.mui.ac.ir
2
Assistant Professor, Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Reyhaneh
Zavar
3
Assistant Professor, Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Ali
Eghbal
4
Resident, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18): 2370-5.
1
Chambers PW. Lone atrial fibrillation: Pathologic or not? Med Hypotheses 2007; 68(2): 281-7.
2
Aronow WS. Management of the older person with atrial fibrillation. J Gerontol A Biol Sci Med Sci 2002; 57(6): M352-M363.
3
Elezi S, Qerkini G, Bujupi L, Shabani D, Bajraktari G. Management and comorbidities of atrial fibrillation in patients admitted in cardiology service in Kosovo-a single-center study. Anadolu Kardiyol Derg 2010; 10(1): 36-40.
4
Agarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs 2010; 10(1): 37-48.
5
Altmann DR, Kuhne M, Sticherling C, Osswald S, Schaer BA. Use of the CHADS2 risk score to guide antithrombotic treatment in patients with atrial fibrillation-room for improvement. Swiss Med Wkly 2010; 140(5-6): 73-7.
6
O'Brien PJ, Thiemann DR, McNamara RL, Roberts JW, Raska K, Oppenheimer SM, et al. Usefulness of transesophageal echocardiography in predicting mortality and morbidity in stroke patients without clinically known cardiac sources of embolus. Am J Cardiol 1998; 81(9): 1144-51.
7
Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31(7): 1622-6.
8
Demircelik MB, Cetin M, Cicekcioglu H, Ucar O, Duran M. Effect of left ventricular diastolic dysfunction on left atrial appendage function and thrombotic potential in nonvalvular atrial fibrillation. Anadolu Kardiyol Derg 2014; 14(3): 256-60.
9
Sarrafzadegan N, Sadeghi M, Gharipour M, Talaiei M, Shafie D, Aghababaie E. Left ventricular diastolic function in subjects with metabolic syndrome: Isfahan Cohort Study. Iran Heart J 2013; 13(4): 63-71.
10
Aalami Harandi S, Sarrafzadegan N, Sadeghi M, Talaei M, Dianatkhah M, Oveisgharan S, et al. Do cardiometabolic risk factors relative risks differ for the occurrence of ischemic heart disease and stroke? Res Cardiovasc Med 2016; 5(1): e30619.
11
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191-4.
12
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2016; 29(4): 277-314.
13
Hopps S, Marcy TR. Warfarin versus aspirin: Using CHADS2 to guide therapy for stroke prevention in nonvalvular atrial fibrillation. Consult Pharm 2009; 24(11): 841-4.
14
Medi C, Hankey GJ, Freedman SB. Atrial fibrillation. Med J Aust 2007; 186(4): 197-202.
15
Schaer BA, Zellweger MJ, Cron TA, Kaiser CA, Osswald S. Value of routine holter monitoring for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemic events. Stroke 2004; 35(3): e68-e70.
16
Todo K, Moriwaki H, Saito K, Naritomi H. Frequent premature atrial contractions in stroke of undetermined etiology. Eur Neurol 2009; 61(5): 285-8.
17
Kosiuk J, Breithardt O, Bode K, Kornej J, Arya A, Gaspar T, et al. Left ventricular diastolic dysfunction and thromboembolic risk in atrial fibrillation: Diastolic dysfunction and thromboembolic risk in AF. Int J Cardiol 2013; 168(1): 547-8.
18
ORIGINAL_ARTICLE
Journal Index
Click to download the index of this issue.
https://arya.mui.ac.ir/article_10603_4b0b4e78849487295b858d6439cfa935.pdf
2017-11-01
Index
Journal
arya@mui.ac.ir
1
LEAD_AUTHOR